Page 28 - BH-1-2

Brain & Heart Pemafibrate in patients with dyslipidemia

Ethics approval and consent to participate lipids, apolipoproteins, and risk of vascular disease. JAMA,
302: 1993–2000.
Not applicable.
https://doi.org/10.1001/jama.2009.1619
Consent for publication 8. Jorgensen AB, Frikke-Schmidt R, West AS, et al., 2013,

Not applicable. Genetically elevated non-fasting triglycerides and calculated
remnant cholesterol as causal risk factors for myocardial
Availability of data infarction. Eur Heart J, 34: 1826–1833.

All data utilized in our analyses were sourced from publicly https://doi.org/10.1093/eurheartj/ehs431
available information within the referenced articles. 9. Nordestgaard BG, Benn M, Schnohr P, et al., 2007,
Nonfasting triglycerides and risk of myocardial infarction,
Further disclosure ischemic heart disease, and death in men and women.
The abstract of this paper was presented at the International JAMA, 298: 299–308.
Congress of Endocrinology – ENDO2023 in June 2023, https://doi.org/10.1001/jama.298.3.299
Chicago, organized by the Endocrine Society. 10. Bansal AB, Cassagnol M, 2023, HMG-CoA reductase

References inhibitors. In: StatPearls. Treasure Island, FL: StatPearls
Publishing. Available from: https://www.ncbi.nlm.nih.gov/
1. World Health Organization, 2021, WHO Cardiovascular books/NBK542212/ [Last accessed on 2022 Jul 04].
Disease Statistics. Available from: https://www.who.int/ 11. Keech A, Simes RJ, Barter P, et al., 2005, Effects of long-
news-room/fact-sheets/detail/cardiovasculardiseases- term fenofibrate therapy on cardiovascular events in 9795
(cvds) Last accessed on 2023 May 13].
[
people with type 2 diabetes mellitus (the FIELD study):
2. Virani SS, Alonso A, Aparicio HJ, et al., 2021, Heart disease Randomised controlled trial. Lancet, 366: 1849–1861.
and stroke statistics-2021 Update: A report from the https://doi.org/10.1016/S0140-6736(05)67667-2. Erratum
american heart association. Circulation, 143: e254–e743.
in: Lancet, 2006, 368: 1420. Erratum in: Lancet, 2006,
https://doi.org/10.1161/CIR.0000000000000950 368: 1415.
3. Stone NJ, Robinson JG, Lichtenstein AH, et al., 2014, 12. Staels B, Dallongeville J, Auwerx J, et al., 1998, Mechanism
2013 ACC/AHA guideline on the treatment of blood of action of fibrates on lipid and lipoprotein metabolism.
cholesterol to reduce atherosclerotic cardiovascular risk Circulation, 98: 2088–2093.
in adults: A report of the American college of cardiology/
American heart association task force on practice guidelines. https://doi.org/10.1161/01.cir.98.19.2088
J Am Coll Cardiol, 63: 2889–2934. 13. Jun M, Foote C, Lv J, et al., 2010, Effects of fibrates on
https://doi.org/10.1016/j.jacc.2013.11.002 cardiovascular outcomes: A systematic review and meta-
analysis. Lancet, 375: 1875–1884.
4. Teramoto T, Sasaki J, Ishibashi S, et al., 2013, Executive
summary of the Japan atherosclerosis society (JAS) https://doi.org/10.1016/S0140-6736(10)60656-3
guidelines for the diagnosis and prevention of atherosclerotic 14. Davidson MH, Armani A, McKenney JM, et al., 2007,
cardiovascular diseases in Japan-2012 version. J Atheroscler Safety considerations with fibrate therapy. Am J Cardiol,
Thromb, 20: 517–523. 99: 3C–18C.
https://doi.org/10.5551/jat.15792 https://doi.org/10.1016/j.amjcard.2006.11.016

5. Baigent C, Blackwell L, Emberson J, et al., 2010, Efficacy 15. Arai H, Yamashita S, Yokote K, et al., 2018, Efficacy and
and safety of more intensive lowering of LDL cholesterol: safety of pemafibrate versus fenofibrate in patients with high
A meta-analysis of data from 170,000 participants in 26 triglyceride and low HDL cholesterol levels: A multicenter,
randomised trials. Lancet, 376: 1670–1681. placebo-controlled, double-blind, randomized trial.
https://doi.org/10.1016/S0140-6736(10)61350-5 J Atheroscler Thromb, 25: 521–538.
6. Carey VJ, Bishop L, Laranjo N, et al., 2010, Contribution of https://doi.org/10.5551/jat.44412
high plasma triglycerides and low high-density lipoprotein 16. Ishibashi S, Arai H, Yokote K, et al., 2018, Efficacy and safety
cholesterol to residual risk of coronary heart disease after of pemafibrate (K-877), a selective peroxisome proliferator-
establishment of low-density lipoprotein cholesterol control. activated receptor α modulator, in patients with dyslipidemia:
Am J Cardiol, 106: 757–763. Results from a 24-week, randomized, double blind, active-
https://doi.org/10.1016/j.amjcard.2010.05.002 controlled, phase 3 trial. J Clin Lipidol, 12: 173–184.
7. Di Angelantonio E, Sarwar N, Perry P, et al., 2009, Major https://doi.org/10.1016/j.jacl.2017.10.006

Volume 1 Issue 2 (2023) 12 https://doi.org/10.36922/bh.1629